1-(2-乙基苄基)吡咯烷 | 102686-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-乙基苄基)吡咯烷
• 英文名称: 1-(2-ethylbenzyl)pyrrolidine
• 英文别名: 1-[(2-Ethylphenyl)methyl]pyrrolidine
• CAS: 102686-41-9
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: DYLDETGXBCSOPN-UHFFFAOYSA-N

物化性质

• 沸点：
  259.0±9.0 °C(predicted)
• 密度：
  0.991±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-羟基异喹啉 在 palladium on activated charcoal 氢氧化钾 、 lithium aluminium tetrahydride 、 氢气 、 四丁基硫酸氢铵 作用下， 以 四氢呋喃 、 甲醇 、 苯 为溶剂， 反应 3.75h， 生成 1-(2-乙基苄基)吡咯烷
  参考文献：
  名称：

  Kaneko, Chikara; Katagiri, Nobuya; Uchiyama, Keiji, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 10, p. 4160 - 4166

  摘要：

  DOI：

文献信息

• [EN] METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ DÉRIVÉ D'ALIZARINE, NOUVEAU COMPOSÉ DÉRIVÉ D'ALIZARINE, PROCÉDÉ DE MODIFICATION DE SURFACE, FILM DE CONVERSION PHOTOÉLECTRIQUE, ÉLÉMENT DE CONVERSION PHOTOÉLECTRIQUE ET PHOTORÉCEPTEUR ÉLECTROPHOTOGRAPHIQUE
  申请人：FUJIFILM CORP

  公开号：WO2011071130A1

  公开（公告）日：2011-06-16

  The present invention provides a novel alizarin derivative compound and a simplified and low cost method for preparing an alizarin derivative compound including: obtaining a compound represented by Formula (2) using a compound represented by Formula (3); and obtaining an alizarin derivative compound represented by Formula (1) using the compound represented by Formula (2); in Formulae (1) to (3), R1 represents a hydrogen atom or a substituent; n represents an integer of 1 to 3, L represents a specific alkyl group; Q represents an atomic group needed to form an aromatic ring or a heteroaromatic ring with adjacent carbon atoms; and P represents an atomic group which includes an atom(s) selected from a hydrogen atom, a carbon atom, an oxygen atom, a sulfur atom, a silicon atom and a boron atom, and which is needed to form a ring structure group with adjacent two oxygen atoms and two carbon atoms; Formula (1) Formula (2) Formula (3).

  本发明提供了一种新型茜素衍生物化合物以及一种简化且低成本的制备茜素衍生物化合物的方法，包括：使用表示为Formula (3)的化合物获得表示为Formula (2)的化合物；并使用表示为Formula (2)的化合物获得表示为Formula (1)的茜素衍生物化合物；在Formulae (1)到(3)中，R1代表氢原子或取代基；n代表1至3的整数，L代表特定的烷基团；Q代表需要与相邻碳原子形成芳香环或杂芳环的原子团；P代表包括从氢原子、碳原子、氧原子、硫原子、硅原子和硼原子中选择的原子的原子团，并且需要与相邻的两个氧原子和两个碳原子形成环结构团；Formula (1) Formula (2) Formula (3)。
• Crf Receptor Antagonists and Methods Relating Thereto
  申请人：Luo Zhiyong

  公开号：US20070287705A1

  公开（公告）日：2007-12-13

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了CRF受体拮抗剂，其在治疗各种疾病中具有用途，包括治疗温血动物中CRF分泌过多表现的疾病，例如中风。本发明的CRF受体拮抗剂具有以下结构（I），包括立体异构体、前药和其药物可接受的盐，其中R1、R2、R3、Y、Ar和het的定义如下。本发明还揭示了含有CRF受体拮抗剂和药物可接受载体的组合物，以及使用它们的方法。
• METHOD FOR PREPARING ALIZARIN DERIVATIVE COMPOUND, NOVEL ALIZARIN DERIVATIVE COMPOUND, SURFACE MODIFICATION METHOD, PHOTOELECTRIC CONVERSION FILM, PHOTOELECTRIC CONVERSION ELEMENT, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR
  申请人：Takahashi Keita

  公开号：US20120244462A1

  公开（公告）日：2012-09-27

  The present invention provides a novel alizarin derivative compound and a simplified and low cost method for preparing an alizarin derivative compound including: obtaining a compound represented by Formula (2) using a compound represented by Formula (3); and obtaining an alizarin derivative compound represented by Formula (1) using the compound represented by Formula (2); in Formulae (1) to (3), R 1 represents a hydrogen atom or a substituent; n represents an integer of 1 to 3, L represents a specific alkyl group; Q represents an atomic group needed to form an aromatic ring or a heteroaromatic ring with adjacent carbon atoms; and P represents an atomic group which includes an atom(s) selected from a hydrogen atom, a carbon atom, an oxygen atom, a sulfur atom, a silicon atom and a boron atom, and which is needed to form a ring structure group with adjacent two oxygen atoms and two carbon atoms;

  本发明提供了一种新型茜素衍生物化合物和一种简化且低成本的制备茜素衍生物化合物的方法，包括：使用式（3）表示的化合物获得式（2）表示的化合物；使用式（2）表示的化合物获得式（1）表示的茜素衍生物化合物；在式（1）至（3）中，R1表示氢原子或取代基；n表示1至3的整数，L表示特定的烷基基团；Q表示需要与相邻的碳原子形成芳香环或杂芳环的原子基团；P表示包括从氢原子、碳原子、氧原子、硫原子、硅原子和硼原子中选择的一个或多个原子的原子基团，需要与相邻的两个氧原子和两个碳原子形成环状结构基团。
• OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT
  申请人：Shin Nippon Biomedical Laboratories, Ltd.

  公开号：EP2939675A1

  公开（公告）日：2015-11-04

  [Problem] To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. [Solution] This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof

  [问题]提供一种 OCT3 活性抑制剂，其基本骨架不同于传统的 OCT3 活性抑制剂。 解决方案]这种有机阳离子转运体 3 (OCT3) 抑制剂的活性成分包括咪唑并[1,2-a]吡啶衍生物、其药学上可接受的盐或其药学上可接受的溶液
• KANEKO, CHIKARA;KATAGIRI, NOBUYA;UCHIYAMA, KEIJI;YAMADA, TORU, CHEM. AND PHARM. BULL., 1985, 33, N 10, 4160-4166
  作者：KANEKO, CHIKARA、KATAGIRI, NOBUYA、UCHIYAMA, KEIJI、YAMADA, TORU

  DOI：——

  日期：——